XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Nov. 05, 2015
Jun. 24, 2015
Aug. 27, 2016
Aug. 29, 2015
Aug. 27, 2016
Aug. 29, 2015
Feb. 27, 2016
Apr. 02, 2015
Final purchase price                
Stock consideration           $ 240,907    
Final purchase price allocation                
Goodwill     $ 1,715,479   $ 1,715,479   $ 1,713,475  
Unaudited pro forma combined financial data                
Bridge loan commitment fees incurred with the Acquisition by both the Company and EnvisionRx     15,375          
Net revenues     8,029,806 $ 7,664,776 16,213,987 14,312,337    
Less pre-acquisition intercompany revenue       (23,777)   (104,731)    
Pro forma combined revenues     8,029,806 8,005,158 16,213,987 15,943,241    
Income (loss) before income taxes     25,701 37,932 14,804 69,209    
Net income     14,773 21,469 10,185 40,305    
Incremental interest expense on the 6.125% Notes issued on April 2, 2015           (11,097)    
Incremental amortization resulting from fair value adjustments of the identifiable intangible assets       (3,778)   (16,509)    
Debt extinguishment charges incurred by EnvisionRx       (33,205)   (33,205)    
Income tax benefit (expense) relating to pro forma adjustments       (3,294)   (5,966)    
Pro forma net income     $ 14,773 $ 26,208 $ 10,185 $ 48,891    
Basic income per share     $ 0.01 $ 0.03 $ 0.01 $ 0.05    
Diluted income per share     $ 0.01 $ 0.02 $ 0.01 $ 0.05    
Pharmacy Services                
Final purchase price allocation                
Goodwill   $ 1,639,355 $ 1,639,355   $ 1,639,355   1,637,351  
Amount of goodwill deductible for tax purpose   $ 1,368,657            
6.125% senior notes due 2023                
Acquisitions                
Principal amount of debt     $ 1,800,000   $ 1,800,000   $ 1,800,000  
Debt instrument, stated interest rate (as a percent)     6.125%   6.125%   6.125%  
EnvisionRx                
Acquisitions                
Ownership interest (as a percent)   100.00%            
Stock consideration (in shares)   27,754            
Share price   $ 8.68            
Final purchase price                
Cash consideration $ 116,500 $ 1,882,211            
Stock consideration   240,907            
Total   2,123,118            
Final purchase price allocation                
Cash and cash equivalents   103,834            
Accounts receivable   892,678            
Inventories   7,276            
Prepaid expenses and other current assets   13,386            
Total current assets   1,017,174            
Property and equipment   13,196            
Intangible assets(1)   646,600            
Goodwill   1,639,355            
Other assets   7,219            
Total assets acquired   3,323,544            
Accounts payable   491,672            
Reinsurance funds held   381,225            
Other current liabilities(2)   215,770            
Total current liabilities   1,088,667            
Other long term liabilities(3)   111,759            
Total liabilities assumed   1,200,426            
Net assets acquired   2,123,118            
Amount due under the terms of agreement   116,057            
Acquisition costs     $ 6 $ 9,613 $ 6 $ 27,072    
Unaudited pro forma combined financial data                
Transaction costs incurred by both the Company and EnvisionRx       36,754   55,864    
Debt extinguishment charges incurred by EnvisionRx       31,601   31,601    
EnvisionRx | Trademarks                
Final purchase price allocation                
Estimated Fair Value of indefinite lived intangible assets   33,500            
EnvisionRx | Customer relationships                
Final purchase price allocation                
Estimated Fair Value of Finite lived intangible assets   $ 465,000            
Estimated Useful Life   17 years            
EnvisionRx | CMS license                
Final purchase price allocation                
Estimated Fair Value of Finite lived intangible assets   $ 57,500            
Estimated Useful Life   25 years            
EnvisionRx | Claims adjudication and other developed software                
Final purchase price allocation                
Estimated Fair Value of Finite lived intangible assets   $ 59,000            
Estimated Useful Life   7 years            
EnvisionRx | Trademarks                
Final purchase price allocation                
Estimated Fair Value of Finite lived intangible assets   $ 20,100            
Estimated Useful Life   10 years            
EnvisionRx | Backlog                
Final purchase price allocation                
Estimated Fair Value of Finite lived intangible assets   $ 11,500            
Estimated Useful Life   3 years            
EnvisionRx | 6.125% senior notes due 2023                
Acquisitions                
Principal amount of debt               $ 1,800,000
Debt instrument, stated interest rate (as a percent)               6.125%
EnvisionRx                
Unaudited pro forma combined financial data                
Net revenues       364,159   1,735,635    
Income (loss) before income taxes       $ (56,544)   $ (45,307)